Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study

被引：0
|
作者：
Jin, Jie
Zhang, Yi
Zhang, Qike
Liu, Qingchi
Zhou, Hu
Gao, Sujun
Wang, Wei
Dang, Huibing
Chen, Yuqing
Wang, Jishi
Zhao, Peng
Yang, Haiping
Ma, Liangming
Zhao, Qingwei
Suo, Shanshan
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Sch Med, Hangzhou, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Hangzhou, Peoples R China
[3] Gansu Prov Hosp, Dept Hematol, Gansu, Peoples R China
[4] Hebei Med Univ, Dept Hematol, Hosp 1, Shijiazhuang, Peoples R China
[5] Zhengzhou Univ, Dept Hematol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[6] Jilin Univ, Dept Hematol, Affiliated Hosp 1, Changchun, Peoples R China
[7] Qingdao Univ, Affiliated Hosp, Dept Hematol, Med Coll, Qingdao, Peoples R China
[8] First Affiliated Hosp, Dept Hematol, Nanyang Med Coll, Nanyang, Peoples R China
[9] Henan Prov Peoples Hosp, Dept Hematol, Zhengzhou, Peoples R China
[10] Guizhou Med Univ, Dept Hematol, Affiliated Hosp, Guiyang, Peoples R China
[11] Guizhou Med Univ, Dept Hematol, Affiliated Hosp, Guiyang, Peoples R China
[12] Henan Univ Sci & Technol, Dept Hematol, Affiliated Hosp 1, Luoyang, Peoples R China
[13] Shanxi Med Univ, Dept Hematol, Shanxi Bethune Hosp, Taiyuan, Peoples R China
[14] Zhejiang Univ, Affiliated Hosp 1, Dept Clin Pharm, Sch Med, Hangzhou, Peoples R China
[15] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7062
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
    Huang, Huiqiang
    Zhu, Jun
    Yao, Ming
    Kim, Tae Min
    Yoon, Dok Hyun
    Cho, Seok-Goo
    Eom, Hyeon Seok
    Lim, Soon Thye
    Yeh, Su-peng
    Song, Yuqin
    Kwong, Yok Lam
    Kim, Jin Seok
    Jin, Jie
    Shi, Yuankai
    Kim, HyeJin
    Qing, Min
    Zhou, Tianyuan
    Gao, Grace
    Dong, Zongqi
    Qi, Ming
    Kim, Won Seog
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [22] Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
    Huiqiang Huang
    Jun Zhu
    Ming Yao
    Tae Min Kim
    Dok Hyun Yoon
    Seok-Goo Cho
    Hyeon Seok Eom
    Soon Thye Lim
    Su-peng Yeh
    Yuqin Song
    Yok Lam Kwong
    Jin Seok Kim
    Jie Jin
    Yuankai Shi
    HyeJin Kim
    Min Qing
    Tianyuan Zhou
    Grace Gao
    Zongqi Dong
    Ming Qi
    Won Seog Kim
    Journal of Hematology & Oncology, 14
  • [23] OPEN-LABEL, SINGLE-ARM, MULTICENTER CONFIRMATORY PHASE 2 STUDY OF THE BITE® ANTIBODY BLINATUMOMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA
    Topp, M.
    Goekbuget, N.
    Stein, A. S.
    Bargou, R. C.
    Dombret, H.
    Fielding, A. K.
    Ribera, J. M.
    Foa, R.
    Zugmaier, G.
    Holland, C.
    Maniar, T.
    Huber, B.
    Nagorsen, D.
    Kantarjian, H. M.
    HAEMATOLOGICA, 2014, 99 : 258 - 258
  • [24] An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
    Vij, Ravi
    Siegel, David S.
    Jagannath, Sundar
    Jakubowiak, Andrzej J.
    Stewart, Alexander Keith
    McDonagh, Kevin
    Bahlis, Nizar
    Belch, Andrew
    Kunkel, Lori A.
    Wear, Sandra
    Wong, Alvin F.
    Orlowski, Robert Z.
    Wang, Michael
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (06) : 739 - 748
  • [25] Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
    Al-Ali, Haifa Kathrin
    Griesshammer, Martin
    le Coutre, Philipp
    Waller, Cornelius F.
    Liberati, Anna Marina
    Schafhausen, Philippe
    Tavares, Renato
    Giraldo, Pilar
    Foltz, Lynda
    Raanani, Pia
    Gupta, Vikas
    Tannir, Bayane
    Ronco, Julian Perez
    Ghosh, Jagannath
    Martino, Bruno
    Vannucchi, Alessandro M.
    HAEMATOLOGICA, 2016, 101 (09) : 1065 - 1073
  • [26] Phase 2 Study of Pracinostat in Combination with Ruxolitinib in Patients (pts) with Myelofibrosis (MF)
    Bose, Prithviraj
    Pemmaraju, Naveen
    Schroeder, Kurt
    Ferrajoli, Alessandra
    Jabbour, Elias J.
    Daver, Naval
    DiNardo, Courtney D.
    Alvarado, Yesid
    Yilmaz, Musa
    Huynh-Lu, Julie
    Qiao, Wei
    Wang, Xuemei
    Matamoros, Aurelio
    Zhou, Lingsha
    Pierce, Sherry
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2017, 130
  • [27] Assessing the Safety and Efficacy of Ruxolitinib in a Multicenter, Open-Label, Expanded-Access Study in Japanese Patients with Myelofibrosis (MF)
    Kirito, Keita
    Komatsu, Norio
    Shimoda, Kazuya
    Okada, Hikaru
    Amagasaki, Taro
    Yonezu, Toshio
    Akashi, Koichi
    BLOOD, 2015, 126 (23)
  • [28] Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
    Ma, Xinran
    Li, Ling
    Zhang, Lei
    Fu, Xiaorui
    Li, Xin
    Wang, Xinhua
    Wu, Jingjing
    Sun, Zhenchang
    Zhang, Xudong
    Feng, Xiaoyan
    Chang, Yu
    Zhou, Zhiyuan
    Nan, Feifei
    Zhang, Jieming
    Li, Zhaoming
    Zhang, Mingzhi
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 275 - 284
  • [29] Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open-label, single-arm, phase 1/2 study on 10 Japanese patients
    Kurihara, Yuichi
    Yamagami, Jun
    Funakoshi, Takeru
    Ishii, Maki
    Miyamoto, Julia
    Fujio, Yumi
    Kakuta, Risa
    Tanikawa, Akiko
    Aoyama, Yumi
    Iwatsuki, Keiji
    Ishii, Norito
    Hashimoto, Takashi
    Nishie, Wataru
    Shimizu, Hiroshi
    Kouyama, Keisuke
    Amagai, Masayuki
    JOURNAL OF DERMATOLOGY, 2019, 46 (02): : 124 - 130
  • [30] Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results
    Cao, Xinxin
    Jin, Jie
    Cheng, Fu Cheng
    Yi, Shuhua
    Zhao, Weili
    Sun, Zimin
    Yang, Wei
    Li, Dengju
    Cui, Guohui
    Hu, Jianda
    Liu, Ting
    Song, Yongping
    Xu, Bing
    Zhu, Zunmin
    Xu, Wei
    Zhang, Mingzhi
    Li, Sichen
    Wang, Weige
    Zhao, Renbin
    Zhou, Daobin
    BLOOD, 2023, 142
12345